Safety and Efficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock (PulseSE)
Safety and Efficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock: A Randomized-Controlled Pilot Study
This study aims to investigate the efficacy of the Synchronized Cardiac Support treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The current study hypothesizes that SCS treatment with the Novalung ultimate kit SCS provides sufficient cardiocirculatory support compared with continuous flow VA-ECMO Patients with cardiogenic shock, requiring a VA-ECMO for circulatory stabilization will be randomized 1:1 either in the investigational group receiving Synchronized Cardiac Support treatment or continuous VA-ECMO treatment as control group.
SCS describes an electrocardiogram (ECG)-triggered pulsatile VA-ECMO based on R-wave detection. During diastole the pump speed and thus the blood flow is increased and during systole the pump flow is set to a relative minimum. This provides a mechanical circulatory support pulse with increased oxygenated blood supply during diastole. The SCS treatment will start as soon the heart rate of the patient is below 110 bpm.
SCS is used in a standard VA-ECMO configuration by two femoral single vessel cannulas according to local practice of study site The duration of the treatment can be up to 14 days.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Fiona Bellando
- Phone Number: +49 6172 8868776
- Email: fiona.bellando@freseniusmedicalcare.com
Study Locations
-
-
-
Prague, Czechia, 150 06
- Motol University Hospital
-
Contact:
- Petr Ostadal, Prof. MD
- Email: petr.ostadal@lfmotol.cuni.cz
-
Prague, Czechia, 128 08
- General University Hospital Prague
-
Contact:
- Jan Bělohlávek, Prof. MD
- Email: jan.belohlavek@vfn.cz
-
-
-
-
-
Essen, Germany, 45138
- Elisabeth-Krankenhaus Essen GmbH
-
Contact:
- Voigt Ingo, Dr med
- Email: I.Voigt@contilia.de
-
-
-
-
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Contact:
- Sandra Ofelia Rosillo Rodriguez, Dr. med.
- Email: sorrph17@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Given the exploratory nature of this randomized study, no formal sample size calculation for between-group comparisons was performed.
Assuming that about 20% of the patients will not provide serum lactate levels at 8 hours after the start of SCS treatment in the Pulse SE study, a total of 50 patients will be enrolled, with 25 patients per treatment group.
This sample size is considered adequate to allow descriptive and exploratory comparisons within and between treatment groups and to estimate effect sizes for the primary and secondary endpoints which will inform the design and sample size planning of future confirmatory studies.
The patients will be enrolled in 4 study centres across Europe.
Inclusion criteria:
-
Informed consent signed and dated by study patient/legal representative or investigator/authorized physician
-
Minimum age of 18 years
-
Patients in cardiogenic shock, defined as SCAI C OR D, with evidence of hemodynamic compromise and hypoperfusion:
-
Hemodynamic compromise (low cardiac output and elevated filling pressures):
- Cardiac index < 2.2 l/min/m2 (invasive or non-invasive measurement)
- Central venous pressure > 7 mmHg OR pulmonary artery occlusion pressure > 12 mmHg OR left-ventricular end-diastolic pressure ˃ 12 mmHg OR B-lines on lung ultrasound
-
Hypoperfusion:
- Lactate ≥ 2 mmol/L OR SvO2 < 65% OR capillary refill time > 3 s OR pCO2 Gap > 0.8 kPa (>6 mmHg)
Exclusion criteria:
- In case of female patients: pregnancy or lactation period (if patient is ≥ 55 years old or have been surgically sterilized, a negative pregnancy test is not required)
- Participation in an interventional clinical study during the preceding 30 days
- Previous participation in the same study
- Age > 75 years
- Out of hospital cardiac arrest with return of spontaneous circulation (ROSC) > 30 min OR non-witnessed cardiac arrest or no flow time > 5 min
- Non-cardiogenic causes of shock (sepsis, hypovolemia, etc.)
- Bradycardia or tachycardia as a cause of shock
- Fever (Body temperature > 38.0 °C) or other evidence of sepsis
- Onset of cardiogenic shock > 4 h before enrolment
- Lactate > 16 mmol/L
- Severe peripheral arterial occlusive disease precluding insertion of femoral arterial or venous catheters
- Contraindications for anticoagulation
- Planned use of primary unloading or venting devices at randomization (e.g. Impella or IABP)
- Contraindication for VA-ECMO, e.g. severe aortic regurgitation, aortic dissection, limited life expectation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SCS Group
Investigational group receiving Synchronized Cardiac Support treatment |
Patients receiving Synchronized Cardiac Support (SCS) treatment with the Novalung ultimate kit SCS and the Xenios 2.0 - Pulsatile flow |
|
Other: Control Group VA-ECMO treatment
Control group receiving continous VA-ECMO treatment |
Patients receiving continuous flow VA-ECMO with the Novalung ultimate kit SCS and the Xenios 2.0 (Standard of care) |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiocirculatory stabilization and end-organ perfusion
Time Frame: Baseline and during the ECMO treatment up to 7 days
|
Lactate clearance at 8 hours after randomization between SCS treatment and continuous flow VA-ECMO using the Novalung ultimate kit SCS will be assessed in an exploratory analysis via venous blood gas analysis (BGA) |
Baseline and during the ECMO treatment up to 7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance objective - Cardiocirculation
Time Frame: Baseline and during the ECMO treatment up to 7 days
|
Improvement and maintenance of patients' cardiocirculation (= cardiocirculatory stabilization). |
Baseline and during the ECMO treatment up to 7 days
|
|
Performance objective - Cardiac Output
Time Frame: Baseline and during the ECMO treatment up to 7 days
|
Cardiac output measured using a pulmonary artery catheter (L/min) |
Baseline and during the ECMO treatment up to 7 days
|
|
Performance objective - organ perfusion
Time Frame: Baseline and during the ECMO treatment up to 7 days
|
Improvement of end-organ perfusion |
Baseline and during the ECMO treatment up to 7 days
|
|
Blood gas analysis
Time Frame: Baseline and during the ECMO treatment up to 7 days
|
Assessment of blood gas parameters by arterial blood gas analysis |
Baseline and during the ECMO treatment up to 7 days
|
|
ECLS performance - blood flow
Time Frame: Baseline and during the ECMO treatment up to 7 days
|
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Maintenance of blood flow (L/min) |
Baseline and during the ECMO treatment up to 7 days
|
|
ECLS performance - Pump speed
Time Frame: Baseline and during the ECMO treatment up to 7 days
|
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): pump speed (rpm) |
Baseline and during the ECMO treatment up to 7 days
|
|
ECLS performance - Circuit pressures
Time Frame: Baseline and during the ECMO treatment up to 7 days
|
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Circuit pressures (mmHg) |
Baseline and during the ECMO treatment up to 7 days
|
|
Safety objectives
Time Frame: Baseline and during the ECMO treatment up to 7 days
|
Assessment of the safety of the SCS treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO |
Baseline and during the ECMO treatment up to 7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ingo Voigt, Dr. med., Elisabeth-Krankenhaus Essen
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CS-SCS-02-EU
- CIV-26-06-058894 (Other Identifier: Eudamed-ID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.